Want to see JP:4599 full AI Analyst Report?
Top Page
StemRIM Inc.
(4599)
Select Model
Select Model
Rating:40Underperform
Price Target:
¥171.00
▼(-32.94% Downside)
Action:Reiterated
Date:09/12/26
The score is driven primarily by very weak financial performance (zero revenue in 2024–2026, large losses, and sustained negative free cash flow), which raises funding/runway risk despite a low-debt balance sheet. Technicals add further pressure, with the price far below key moving averages and bearish momentum. Valuation does not offset these risks because the negative P/E reflects ongoing losses and there is no dividend yield support.
Positive Factors
Debt-Free Balance Sheet
The absence of meaningful debt reduces leverage and interest-burden risk, giving StemRIM more flexibility than a similarly unprofitable company with heavy borrowing. This provides a modest financial buffer while management works to restore commercialization and cash generation.
Negative Factors
Zero Revenue and Expanding Losses
Three consecutive years of zero reported revenue combined with losses near ¥2B demonstrate that StemRIM is not currently converting its activities into commercial income. Persistent unprofitability weakens earnings visibility, erodes capital, and increases dependence on future financing or business recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
The absence of meaningful debt reduces leverage and interest-burden risk, giving StemRIM more flexibility than a similarly unprofitable company with heavy borrowing. This provides a modest financial buffer while management works to restore commercialization and cash generation.
Read all positive factors
StemRIM Inc. (4599) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥11.09B
Dividend YieldN/A
Average Volume (3M)651.53K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue GrowthN/A
EPS Growth4.68%
CountryJP
Employees45
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-29.69
Shares Outstanding62,681,200
10 Day Avg. Volume1,160,220
30 Day Avg. Volume651,526
Financial Highlights & Ratios
PEG Ratio2.05
Price to Book (P/B)3.26
Price to Sales (P/S)0.00
P/FCF Ratio-11.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.8
Revenue Forecast (FY)¥540.00M
StemRIM Inc. Business Overview & Revenue Model
Company Description
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently under...
StemRIM Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
24
Negative
| Breakdown | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 2.35B | 22.98M |
| Gross Profit | -38.36M | -49.50M | -44.35M | 2.30B | 22.98M |
| EBITDA | -1.96B | -1.92B | -2.03B | 190.18M | -1.93B |
| Net Income | -1.85B | -1.93B | -2.02B | 168.35M | -1.95B |
Balance Sheet | |||||
| Total Assets | 5.91B | 7.52B | 9.09B | 10.72B | 9.61B |
| Cash, Cash Equivalents and Short-Term Investments | 5.38B | 6.99B | 8.41B | 10.22B | 8.88B |
| Total Debt | 0.00 | 0.00 | 0.00 | 531.00K | 3.67M |
| Total Liabilities | 196.04M | 210.27M | 194.06M | 348.51M | 207.74M |
| Stockholders Equity | 5.71B | 7.31B | 8.89B | 10.37B | 9.40B |
Cash Flow | |||||
| Free Cash Flow | -1.62B | -1.46B | -1.88B | 1.14B | -1.40B |
| Operating Cash Flow | -1.61B | -1.41B | -1.88B | 1.14B | -1.40B |
| Investing Cash Flow | -3.21B | -42.50M | -4.78M | -344.00K | -330.00K |
| Financing Cash Flow | 0.00 | 41.25M | 78.97M | 202.60M | 112.86M |
StemRIM Inc. Technical Analysis
Negative
255.00
Price Trends
301.46
Negative
300.03
Negative
293.86
Negative
Market Momentum
-40.75
Positive
21.14
Positive
3.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4599, the sentiment is Negative. The current price of 255 is below the 20-day moving average (MA) of 283.20, below the 50-day MA of 301.46, and below the 200-day MA of 293.86, indicating a bearish trend. The MACD of -40.75 indicates Positive momentum. The RSI at 21.14 is Positive, neither overbought nor oversold. The STOCH value of 3.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4599.
StemRIM Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥6.41B | 64.99 | ― | 1.55% | -9.94% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | ¥41.21B | 61.29 | ― | ― | -47.32% | ― | |
46 Neutral | ¥34.44B | -78.23 | ― | ― | 3.43% | -53.59% | |
44 Neutral | ¥14.34B | -30.07 | ― | ― | -18.71% | -246.54% | |
44 Neutral | ¥9.04B | -7.91 | ― | ― | -56.16% | 3.12% | |
40 Underperform | ¥11.09B | -5.96 | ― | ― | ― | 4.68% |
* General Sector Average
JP:4599
StemRIM Inc.
177.00
-126.00
-41.58%
JP:4593
Healios KK
304.00
-318.00
-51.13%
JP:4880
CellSource Co., Ltd.
323.00
-254.20
-44.04%
JP:4978
ReproCELL Inc.
138.00
-66.00
-32.35%
JP:7774
Japan Tissue Engineering Co., Ltd.
848.00
334.00
64.98%
JP:7776
CellSeed Inc.
229.00
-254.00
-52.59%
StemRIM Inc. Corporate Events
StemRIM Grants New Stock Options to Directors as Regenerative Medicine Pipeline Advances
Sep 10, 2026
StemRIM Inc. has set final terms for its 20th series of stock acquisition rights, issuing 3,000 stock option units to four directors, representing rights to acquire 300,000 common shares at an exercise price of 24,500 yen per unit. The move unders...
StemRIM Sets Terms for New Employee Stock Option Issuance
Sep 10, 2026
StemRIM Inc. has approved detailed terms for its 19th series of stock acquisition rights to be granted as stock options to employees, issuing 4,989 units corresponding to 498,900 common shares. The options, allocated to 47 employees at an exercise...
StemRIM Deepens Losses but Secures Funding for Regenerative Medicine Push
Sep 9, 2026
StemRIM Inc. reported another year of operating losses for the fiscal year ended July 31, 2026, with net income remaining in the red and equity per share declining as total assets and net assets fell. Cash and cash equivalents dropped sharply as o...
StemRIM Issues New Director Stock Options With Limited Dilution
Sep 9, 2026
StemRIM Inc. has approved the issuance of its 20th series of stock acquisition rights as stock options to directors, under a previously sanctioned remuneration framework that caps annual stock option value for directors and corporate auditors. The...
StemRIM Issues New Employee Stock Options With Limited Dilution Impact
Sep 9, 2026
StemRIM Inc. has approved the issuance of its 19th series of stock acquisition rights as stock options to employees, with up to 4,989 units convertible into 498,900 shares of common stock. The options, issued without payment and exercisable betwee...
StemRIM Secures South Korean Patent for Gene Therapy Targeting Rare Skin Disease
Aug 3, 2026
StemRIM Inc. said it has secured patent protection in South Korea for its stem cell gene therapy technology SR-GT1, designed as a curative treatment for dystrophic epidermolysis bullosa, a severe hereditary skin disorder caused by defects in type ...
StemRIM Wins Mexican Patent for Redasemtide Cartilage Therapy
Jul 22, 2026
StemRIM Inc. said it will soon secure a patent in Mexico for using its peptide drug Redasemtide as a therapeutic agent for cartilage disorders, including traumatic defects, osteoarthritis and osteochondritis dissecans. The patent, filed jointly wi...
StemRIM Secures Canadian Patent for Regenerative Heart Drug Redasemtide
Jul 13, 2026
StemRIM Inc. said a medical use patent for its Regeneration-Inducing Medicine candidate Redasemtide, covering cardiomyopathy, old myocardial infarction and chronic heart failure, is set to be registered in Canada, adding to existing protection in ...
StemRIM Wins South Korean Patent for Gene Therapy Targeting Rare Skin Disorder
Jul 8, 2026
StemRIM Inc. has secured patent protection in South Korea for a stem cell gene therapy technology, codenamed SR-GT1, aimed at providing a curative treatment for dystrophic epidermolysis bullosa, a severe hereditary skin disorder caused by defects ...
StemRIM to Record AMED Subsidy as Non-Operating Income for Gene Therapy Project
Jun 19, 2026
StemRIM Inc. said it will book non-operating income in the fourth quarter of the fiscal year ending July 31, 2026, after a subsidy for its regenerative medicine project was finalized. The company has secured 59.973 million yen in subsidy income fo...
StemRIM Wins Australian Patent for Redasemtide Cartilage Disorder Therapy
Jun 17, 2026
StemRIM Inc. has secured imminent patent registration in Australia for the use of its HMGB1 fragment peptide drug candidate Redasemtide as a therapeutic agent for cartilage disorders, including traumatic cartilage defects of the joint, osteoarthri...
StemRIM Wins Russian Patent to Expand Redasemtide Use in Fatty Liver and NASH
Jun 16, 2026
StemRIM Inc. has announced that a medical use patent for its regeneration-inducing drug candidate Redasemtide, covering a new therapeutic indication for fatty liver and non-alcoholic steatohepatitis, will soon be registered in Russia. The patent, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.